Secondary Sclerosis Cholangitis Prospective

Study acronym: SSCpro
StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 11 months later Dec 2026 → Dec 2028
See other at-risk trials from Medical University of Graz

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 2026 to Dec 2028 Show 5 more changesShow less
    • Enrollment closed, study ongoing
    • Study completion pushed from Dec 2027 to Dec 2029
    • Study description revised
    • Site details revised
    • Eligibility criteria expanded, about 4 words
  2. Re-verified, no change to tracked fieldsv8
  3. Primary completion date: Jun 1, 2023 to Dec 2026
    • Study completion date: Jun 1, 2024 to Dec 2027
    v7
  4. Re-verified, no change to tracked fieldsv6
  5. Primary completion date: Jun 1, 2021 to Jun 1, 2023
    • Study completion date: Jun 1, 2022 to Jun 1, 2024
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. 2 versions Re-verified since Aug 7, 2019, no change to tracked fieldsv3-v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 1, 2018 to Jul 20, 2018
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
SC-CIP is increasing in patients after critical illness. Pathogenesis is still largely unclear. Gut microbiome composition, gut permeability, bacterial translocation, inflammation and/or genetic variants contribute to the pathogenesis The aim of this project is to study gut microbiome composition, gut permeability, bacterial translocation, inflammation, bile acid composition and genetic polymorphisms by conducting a prospective cohort study in patients with a high risk to develop SC-CIP.
Trial Details
NCT Number NCT03566797
Lead Sponsor Medical University of Graz
Conditions
(from sponsor)		 Secondary Sclerosis Cholangitis in Critically Ill Patients
Enrollment 380 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov